Association of Androgen Deprivation Therapy with Osteoporotic Fracture in Patients with Prostate Cancer with Low Tumor Burden Using a Retrospective Population-Based Propensity-Score-Matched Cohort

Kim, Sung-Han; Jeon, Youn Soo; Bak, Jean Kyung; Yoo, Bit-Na; Park, Jung-Wee; Ha, Yong‐Chan; Lee, Yong Seuk

doi:10.3390/cancers15102822

Cited by 1 publication

(1 citation statement)

References 31 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, fractures during ADT therapy have been reported. During a mean follow-up period of 47.7 months, 977 patients (3.43%) developed osteoporosis fracture (OF), and the incidence of hip, spine, and wrist fractures differed significantly between the ADT and non-ADT groups [17]. The incidence of OF was significantly higher in the ADT group than in the non-ADT group, and the incidence of spine, hip, and wrist fractures was significantly higher in the ADT group than in the non-ADT group, regardless of the stage of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan

Nishimoto,

Inui,

Mifune

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Androgen deprivation therapy (ADT) for prostate cancer has greatly improved treatment outcomes. As patient survival rates have increased, reports of decreased bone density and increased bone fractures as side effects of ADT have emerged. The prevalence of osteoporosis in Japanese men was 4.6%. The purpose of this study was to evaluate the effect of osteoporosis treatment in prostate cancer patients who underwent ADT in Japan. Materials and Methods: The subjects were 33 male patients who had undergone ADT for prostate cancer, who were noted to have decreased bone density. Mean age was 76.2 ± 7.7 years (64–87). Medications included vitamin D in one case, bisphosphonates (BP) in 27 cases, and denosumab in five cases. The evaluation method examined the rate of change in bone mineral density (BMD) before osteoporosis treatment and 1 year after. For comparison, a group without osteoporosis treatment intervention (n = 33) was selected, and matched for prostate cancer treatment and age. The rate of change in trabecular bone score (TBS) was also calculated. Results: The percentage changes in BMD before and 1 year after treatment were as follows: lumbar spine, 7.1 ± 5.8% in the treatment group versus −3.9 ± 4.1% in the no treatment group; femoral neck, 5.5 ± 6.2% in the treatment group versus −0.9 ± 3.9% in the no treatment group; total femur, 6.6 ± 6.4% in the treatment group versus the no treatment group which was −1.7 ± 3.2%. In all cases, there was a clear significant difference (p < 0.01). The percent change in TBS was further calculated in the same manner. There was no significant difference between the two groups: +1.7 ± 3.8% in the treated group versus +0.3 ± 4.1% in the untreated group. Conclusions: Osteoporosis treatment in Japanese patients with prostate cancer on ADT therapy was found to significantly increase BMD compared to the untreated group. BP and denosumab were found to be very effective in increasing BMD.

show abstract

Section: Discussionmentioning

confidence: 99%